Id: acc2513
Group: 2sens
Protein: PD-L1
Gene Symbol: CD274
Protein Id: Q9NZQ7
Protein Name: PD1L1_HUMAN
PTM: ubiquitination
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype: NSCLC
Disease Cellline: A549
Disease Info:
Drug: DHA
Drug Info: -
Effect: modulate
Effect Info: DHA can promote the ubiquitin - proteasome degradation of PD - L1 and reverse the PD - L1 - mediated immunosuppression.
Note:
Score: 4.0
Pubmed(PMID): 36309154
Sentence Index:
Sentence:

Sequence & Structure:

MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
CD274 ATEZOLIZUMAB Programmed cell death 1 ligand 1 inhibitor 4 - neoplasm ATC
CD274 AVELUMAB Programmed cell death 1 ligand 1 other 4 - neoplasm ATC
CD274 DURVALUMAB Programmed cell death 1 ligand 1 inhibitor 4 - neoplasm ATC
CD274 DURVALUMAB Programmed cell death 1 ligand 1 inhibitor 4 Active, not recruiting neoplasm ClinicalTrials
CD274 ATEZOLIZUMAB Programmed cell death 1 ligand 1 inhibitor 4 - small cell lung carcinoma EMA
CD274 DURVALUMAB Programmed cell death 1 ligand 1 inhibitor 4 - small cell lung carcinoma DailyMed
CD274 DURVALUMAB Programmed cell death 1 ligand 1 inhibitor 4 Completed non-small cell lung carcinoma ClinicalTrials
CD274 DURVALUMAB Programmed cell death 1 ligand 1 inhibitor 4 - non-small cell lung carcinoma FDA
EMA
CD274 ATEZOLIZUMAB Programmed cell death 1 ligand 1 inhibitor 4 - non-small cell lung carcinoma EMA
CD274 ATEZOLIZUMAB Programmed cell death 1 ligand 1 inhibitor 4 Completed non-small cell lung carcinoma ClinicalTrials
CD274 ATEZOLIZUMAB Programmed cell death 1 ligand 1 inhibitor 4 Recruiting non-small cell lung carcinoma ClinicalTrials
CD274 ATEZOLIZUMAB Programmed cell death 1 ligand 1 inhibitor 4 - breast neoplasm EMA
CD274 AVELUMAB Programmed cell death 1 ligand 1 other 4 - urothelial carcinoma DailyMed
CD274 ATEZOLIZUMAB Programmed cell death 1 ligand 1 inhibitor 4 - urothelial carcinoma DailyMed
CD274 ATEZOLIZUMAB Programmed cell death 1 ligand 1 inhibitor 4 - Transitional Cell Carcinoma EMA
CD274 AVELUMAB Programmed cell death 1 ligand 1 other 4 - neuroendocrine neoplasm EMA
CD274 AVELUMAB Programmed cell death 1 ligand 1 other 4 - Merkel cell skin cancer FDA
DailyMed
CD274 ATEZOLIZUMAB Programmed cell death 1 ligand 1 inhibitor 4 - benign urinary system neoplasm EMA
CD274 DURVALUMAB Programmed cell death 1 ligand 1 inhibitor 4 - urinary bladder carcinoma FDA
CD274 ATEZOLIZUMAB Programmed cell death 1 ligand 1 inhibitor 4 - breast cancer DailyMed
CD274 DURVALUMAB Programmed cell death 1 ligand 1 inhibitor 4 - lung cancer DailyMed
CD274 ATEZOLIZUMAB Programmed cell death 1 ligand 1 inhibitor 4 - lung cancer DailyMed
CD274 DURVALUMAB Programmed cell death 1 ligand 1 inhibitor 3 Withdrawn head and neck squamous cell carcinoma ClinicalTrials
CD274 DURVALUMAB Programmed cell death 1 ligand 1 inhibitor 3 Active, not recruiting hepatocellular carcinoma ClinicalTrials
ClinicalTrials
ClinicalTrials
CD274 DURVALUMAB Programmed cell death 1 ligand 1 inhibitor 3 Recruiting hepatocellular carcinoma ClinicalTrials
ClinicalTrials
ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - U Triple-negative breast cancer Glycosylation 35538152
- - U Nasopharyngeal carcinoma Glycosylation 35311117
- - U Pancreatic cancer Ubiquitination 34325342
- - U Non-small cell lung cancer Ubiquitination 34741014

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: